Volume : 09, Issue : 08, August – 2022
Title:
27.UPDATED S2K GUIDELINES ON THE MANAGEMENT OF PEMPHIGUS VULGARIS AND FOLIACEUS
Authors :
Dr. Lubna Zahir, Dr. Umer Jaleel Rana, Dr Muhammad Haider Hayat, Dr Sundas Fahim
Abstract :
Background: This study is based on the protection and treatment of skin and the mucous membrane. Some diseases which occur due to the threatening of life and issues related to skin. They use some immune treatment and this disease is known as fatal disease. To treat this issue, they use several types of therapies and treatments related to this disease and prevent hazardous effects.
Objectives: The main objective of this study is to treat the disease and the development of this disease among patients. Patients need proper guideline and treatment related to this disease and a proper management of this disease is needed.
Results: Some guidelines were needed to measure the development and treatment related to this disease. They provide all types of treatments to patients suffering from the pemphigus disease show severe results. They include all types of task related to this study and show results. Issues and problems arises related to this disease is spreading in the whole world and is increasing rapidly.
Conclusions: All types of issues related to the pemphigus disease which is related to the skin and mucous glands should be treated properly. Awareness related to this issue should be given to the patients. It will help them to cope up with this problem and save their lives. When they were aware the disease and its outcomes, it will be easy for them to treat their disease.
Keywords: pemphigus, management, treatment, catabolism.
Cite This Article:
Please cite this article in press Lubna Zahir et al, Updated S2k Guidelines On The Management Of Pemphigus Vulgaris And Foliaceus., Indo Am. J. P. Sci, 2022; 09(8).
,
Number of Downloads : 10
References:
1. Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R., … & Joly, P. (2022). Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology.
2. Moghadam, F. S., Kianfar, N., Dasdar, S., Samii, R., Farimani, Z., Azar, P. M., … & Daneshpazhooh, M. (2022). Adverse outcome and severity of COVID‐19 in patients with autoimmune bullous diseases: A historical cohort study. Dermatologic Therapy, e15672.
3. Van Huizen, A. M., Vermeulen, F. M., Bik, C. M., Borgonjen, R., Karsch, S. A., Kuin, R. A., … & Spuls, P. I. (2022). On which evidence can we rely when prescribing off-label methotrexate in dermatological practice?–a systematic review with GRADE approach. Journal of Dermatological Treatment, 33(4), 1947-1966.
4. Balighi, K., Hatami, P., Sheikh Aboli, M. J., Daneshpazhooh, M., Ghiasi, M., Mahmoudi, H. R., & Aryanian, Z. (2022). Multiple cycles of rituximab therapy for pemphigus: a group of patients with difficult‐to‐treat disease or a consequence of late rituximab initiation?. Dermatologic Therapy, 35(2), e15249.
5. Daneshvar, E., Tavakolpour, S., Mahmoudi, H., Daneshpazhooh, M., Teimourpour, A., Aslani, S., & Balighi, K. (2022). Elevated serum level of B‐cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with anti‐BAFF agents. International Journal of Dermatology.
6. Werner, R. N., Pennitz, A., Eisert, L., Schmidle, P., Zink, A., Abraham, S., … & Nast, A. (2022). Impact of off‐label use regulations on patient care in dermatology–a prospective study of cost‐coverage applications filed by tertiary dermatology clinics throughout Germany. Journal of the European Academy of Dermatology and Venereology.
7. Bardazzi, F., Filippi, F., Chessa, M. A., Iommi, M., Loi, C., Campanati, A., … & Pitino, A. (2022). Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study. Journal of the European Academy of Dermatology and Venereology.
8. Gutierrez, Y., Pourali, S. P., Singh, I., & Armstrong, A. W. (2022). Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. Journal of Dermatological Treatment, 33(4), 2383-2385.
9. Sharaf, K. H., Mohamed, R. A., & Fadlalmola, H. A. (2022). Application of Henderson Theory on Nursing Care for Bullous Pemphigus Patients at Khartoum Dermatology Hospital, Sudan. International Journal of Nursing Education, 14(1).
10. Daneshpazhooh, M., Patsatsi, A., Vassileva, S., & Murase, J. E. (2022). Blistering disorders and their impact on women and their families in the International Journal of Women’s Dermatology: Honoring the contributions of Professor Dedee Murrell. International Journal of Women’s Dermatology, 8(1), e001.